Skip to content
Research library

Clinical research overview

This library brings together peer-reviewed studies on Mesenchymal Stem Cells (MSCs) across a wide range of medical indications. Each study contributes to a deeper understanding of how MSCs support repair, regeneration, and immune balance in the body.
Crohn's disease Aging frailty Osteoarthritis
Acute respiratory disease syndrome Graft versus host disease (GvHD) Multiple sclerosis Liver cirrhosis Diabetes type II Diabetes type I Chronic low back pain Chronic obstructive pulmonary disease (COPD) Alzheimer's disease Rheumatoid arthritis

Diabetes type II

Mesenchymal Stem Cells (MSCs) are being studied in Type 2 diabetes to investigate potential roles in glucose regulation, insulin sensitivity, and metabolic processes. Type 2 diabetes mellitus (T2DM) is a chronic, progressive metabolic disorder marked by a combination of insulin resistance in muscle, adipose tissue, and the liver, together with a relative deficiency in insulin secretion due to progressive pancreatic β-cell dysfunction. These mechanisms lead to sustained hyperglycemia, often accompanied by dyslipidemia, hypertension, and a prothrombotic state, forming part of the metabolic syndrome. MSC research in Type 2 diabetes is ongoing and aims to clarify whether their biological effects could support future therapeutic strategies. Evidence remains early, but this work is expanding understanding of regenerative medicine in metabolic health.

Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial

Li Zang, et al.
To determine the efficacy and safety of umbilical cord-derived mesenchymal stem cells (UC-MSCs) in Chinese adults with type 2 diabetes mellitus (T2DM).
More
Read study

Type 2 diabetes mellitus duration and obesity alter the efficacy of autologously transplanted bone marrow-derived mesenchymal stem/stromal cells

Liem Thanh Nguyen, et al.
Human bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) represent promising stem cell therapy for the treatment of type 2 diabetes mellitus (T2DM), but the results of autologous BM-MSC administration in T2DM patients are contradictory. The purpose of this study was to test the hypothesis that autologous BM-MSC administration in T2DM patient is safe and that the efficacy of the treatment is dependant on the quality of the autologous BM-MSC population and administration routes.
More
Read study

Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study

Jay S Skyler, et al.
To assess the safety, tolerability, and feasibility of adult allogeneic bone marrow-derived mesenchymal precursor cells (MPCs) in type 2 diabetes inadequately controlled with metformin either alone or with one additional oral antidiabetic agent.
More
Read study

Efficacy of Autologous Bone Marrow-Derived Mesenchymal Stem Cell and Mononuclear Cell Transplantation in Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Comparative Study

Shobhit Bhansali, et al.
Drugs targeting β-cells have provided new options in the management of T2DM; however, their role in β-cell regeneration remains elusive. The recent emergence of cell-based therapies such as autologous bone marrow-derived mesenchymal stem cells (ABM-MSCs) and mononuclear cells (ABM-MNCs) seems to offer a pragmatic approach to augment β-cell function/mass.
More
Read study

Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study

Ranhua Jiang, et al.
MSCs transplantation improved glycated hemoglobin (HbA1c), shifted serum cytokine patterns from pro-inflammatory to anti-inflammatory, increased the number of regulatory T-cells in the peripheral blood, and improved quality of life.
More
Read study

Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus

Dexiao Kong, et al.
Type 2 diabetes mellitus (T2DM) is a serious threat to human health and remains incurable. Insulin deficiency seems to be attributed to the progressive failure of pancreatic islet β-cells and immune cells such as T cells mediated cytotoxicity may be involved in the loss of pancreatic islet β-cells in T2DM.
More
Read study